Investigational antibiotic effective against drug-resistant UTIs in Phase II trial

A Phase II trial has reported that a new investigational antibiotic, cefiderocol, is as effective as the current standard-of-care (imipenem–cilastatin) for treating complicated UTIs caused by multi-drug resistant bacteria.

The findings, published in The Lancet Infectious Diseases, indicate the promise of this siderophore-based compound, demonstrating a higher and more sustained level of pathogen eradication compared with imipenem–cilastatin, in addition to producing similar clinical outcomes.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.


Leave A Comment